Biomarkers of high-grade serous ovarian carcinomas

Patent metadata

Field	Value
Publication number	US-9771620-B2
Application number	US-201414282603-A
Country	US
Kind code	B2
Filing date	May 20, 2014
Priority date	May 20, 2013
Publication date	Sep 26, 2017
Grant date	Sep 26, 2017

Abstract

The present disclosure provides biomarkers useful for determining the prognosis of conditions such as ovarian cancer. The presently disclosed subject matter provides angiogenic biomarkers and methods and compositions for predicting overall survival (OS) in women with high-grade serous carcinomas (HGSCs). The presently disclosed subject matter provides compositions and methods that enable rationally directed therapies to improve outcome in women with HGSC.

First claim

What is claimed is:

1. A method of predicting survival of a subject having high-grade serous ovarian cancer (HGSC), comprising:
quantifying a gene expression level consisting of an ANGPTL3 biomarker in a biological sample derived from the subject having HGSC comprising one or a combination of ovarian tumor tissue, ovarian tumor cells, or ovarian biopsy tissue relative to a reference control for HGSC subjects including those having a survival of 3 years or less and those having a survival of 7 years or more, wherein the quantifying is carried out by one or a combination of Polymerase Chain Reaction, Real Time-Polymerase Chain Reaction, Real Time Reverse Transcriptase-Polymerase Chain Reaction, Real-time quantitative RT-PCR, Northern blot analysis, in situ hybridization, and probe array; and
predicting the subject as having the survival of 3 years or less if the gene expression level of the ANGPTL3 biomarker is higher in the biological sample derived from the subject compared to the reference control.

2. The method of claim 1 , further comprising administering appropriate ovarian cancer therapy to the subject based on the prediction of the survival of 3 years or less.

3. The method of claim 1 , wherein the subject is a mammal.

4. The method of claim 1 , wherein the subject is a human.

Assignees

• Univ Duke

Inventors

• Reihani Sharareh
• Secord Angeles Alvarez
• Dewhirst Mark
• Jiang Chen
• Owzar Kouros

Classifications

• C12Q2600/118

  Prognosis of disease development · CPC title

• C12Q1/6886 Primary

  for cancer (immunoassay for cancer G01N33/575) · CPC title

• C12Q2600/158

  Expression markers · CPC title